The Food and Drug Administration has given Cambridge-based Merrimack Pharmaceuticals' second treatment for pancreatic cancer orphan-drug status, a designation that entitles therapies for rare diseases to tax credits and seven years of market exclusivity if the FDA approves them.
The drug, MM-141, blocks two proteins from signaling the survival of cancer cells, thereby making chemotherapy more effective at killing them, said Ulrik Nielsen, Merrimack's chief scientific officer.
"When tumor cells don't continue to get survival signals, they die on their own when you treat them with chemo," Nielsen said.
The drug, which will begin testing in pancreatic cancer patients next year, could hold promise for the 46,000 people diagnosed each year in the U.S., 40,000 of whom die, typically because they don't respond well to chemotherapy.
Merrimack's other pancreatic cancer drug, MM-398, has completed its final phase of testing in patients, he said. The company is filing for FDA approval for that drug, which also has orphan-drug status.
Anda sedang membaca artikel tentang
Cambridge company gets orphan-drug status
Dengan url
http://wartawanlocal.blogspot.com/2014/11/cambridge-company-gets-orphan-drug.html
Anda boleh menyebar luaskannya atau mengcopy paste-nya
Cambridge company gets orphan-drug status
namun jangan lupa untuk meletakkan link
Cambridge company gets orphan-drug status
sebagai sumbernya
0 komentar:
Posting Komentar